As of July 10, 2026, FDA lists Kyle Diamantas, J.D., as Acting Commissioner of Food and Drugs.
Federal law requires a permanent FDA Commissioner to be appointed by the President with the advice and consent of the Senate. The statute also identifies protection from electronic-product radiation as part of FDA’s mission.
That confirmation process is an opportunity for public accountability.
The public should not ask a nominee to promise a predetermined scientific conclusion before reviewing the evidence. It should ask the nominee to commit publicly to a lawful, current, transparent process.
Every person concerned about this issue should contact both United States senators and ask them to place the following questions into the confirmation record.
Questions for the next FDA Commissioner
- Will you publish a section-by-section accounting of how FDA and HHS are carrying out every program function listed in 21 U.S.C. § 360ii(a)?
- What current research addresses modern wireless technologies, chronic exposure, developmental exposure, modulation, pulsation, intermittency, multiple simultaneous sources, and potentially susceptible populations?
- What research capacity has replaced the completed NIEHS RF program now that NIEHS says its previous system was not representative of newer technologies and that no additional studies are presently planned?
- Will FDA support blinded, preregistered studies comparing different waveforms under matched absorbed-energy and rigorous thermal-control conditions?
- Will FDA publish the scientific analyses and recommendations through which HHS supplies health expertise to the FCC?
- Will you direct and publish a current assessment under § 360kk of whether additional performance standards, test procedures, warnings, labels, or installation and use instructions are necessary?
- Will you identify any funding, personnel, equipment, contracting, or grant deficiencies preventing full execution of § 360ii and request the necessary resources from Congress?
- Will you commit to independent replication, transparent dosimetry, open methods, and publication of both positive and negative findings?
The objective is not to force a nominee to endorse RF Safe’s framework.
The objective is to place the federal government’s answer into the public record.
A message citizens can send
Subject: Public Law 90-602 questions for the next FDA Commissioner
Dear Senator:
Before voting on the next nominee for Commissioner of Food and Drugs, please ask the nominee to explain how FDA and HHS are carrying out the Radiation Control for Health and Safety Act of 1968, now codified at 21 U.S.C. §§ 360hh–360ss.
Please request a public, section-by-section accounting of compliance with § 360ii; a modern research plan addressing contemporary wireless technologies and developmental and long-term exposure; an explanation of what has replaced the completed NIEHS RF-exposure program; publication of the scientific record supplied to the FCC; and a transparent assessment under § 360kk.
I am not asking the nominee to promise a predetermined result. I am asking for a commitment to conduct the work Congress required, publish the evidence, identify research gaps, request necessary resources, and provide a reasoned public determination.
Please place the nominee’s answers in the public confirmation record and send me a written response.
Members of the House of Representatives do not vote on FDA confirmation, but they can request oversight, press HHS for answers, and support or oppose research appropriations. Citizens should contact them as well.
The point is to move from frustration to a documented governmental response:
